Strides Pharma International AG, a subsidiary of Strides Pharma Science Limited, is expanding its presence in the European market with its headquarters in Zug, Switzerland. The move is expected to accelerate technology transfer and innovative developments within the region.
Oren Weininger, a seasoned leader at Fairmed Healthcare, has been appointed as the CEO and Chairman of the Board for Strides Pharma International AG. Weininger brings a wealth of experience to the role, having previously held positions at Dexcel Pharma and Kamedis before joining Fairmed Healthcare in 2014 and taking over as owner in 2018.
Strides Pharma Science Limited, a globally renowned pharmaceutical company with a presence in 100 countries and headquartered in Bangalore, India, is known for its development and manufacturing of IP-led niche finished dosage formulations. With over 30 years of research and development expertise, the company is committed to delivering innovative and cost-effective products to the market. Strides Pharma is also a major manufacturer of Ibuprofen and Macrogol in various forms, and offers a range of drug delivery technologies that cater to the ever-changing needs of the target markets.
Under the newly established Strides Pharma International AG, the company will consolidate its partner-centric in-licensing portfolio of over 250 formulations, which includes generics, sterile injectables, value-added products, Women´s Health hormones, lyophilized orally dissolving tablets, and end-to-end biopharmaceutical CDMO services. This will be done through synergICE, a one-stop-shop for all the company’s products.
In his statement, Weininger expressed excitement about the strengthened European B2B presence of Strides Pharma, which will enable the company to respond more quickly to customers’ needs and offer flexible and innovative solutions. He also highlighted the comprehensive support in supply chain, quality management, and regulatory processes that will be provided by Strides Pharma International AG and the EU GMP-site in Hamburg, Germany.
Key markets for Strides Pharma International AG include Central and Southern Europe, particularly Germany, Scandinavia, Benelux, and the Visegrád countries. For more information, please visit www.fair-med.com/newsroom.
In addition to his new role at Strides Pharma International AG, Weininger will continue to lead Fairmed Healthcare GmbH in Hamburg. Strides Pharma Science Limited, which was established in 1990, has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. The company is a key active pharmaceutical ingredient manufacturer and a major supplier of Ibuprofen tablets globally. For more information, please visit www.strides.com.
For media inquiries, please contact What About Now Agency at Andreas Schöpf at fas@whataboutnow.de or by phone at +49 160 90723690.
This news story has been distributed by Pressat, a UK-based PR company specializing in distributing press releases and news stories to the media. For more information, please visit https://pressat.co.uk/.
